Literature DB >> 7562048

In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.

T Torizuka1, N Tamaki, T Inokuma, Y Magata, S Sasayama, Y Yonekura, A Tanaka, Y Yamaoka, K Yamamoto, J Konishi.   

Abstract

UNLABELLED: The present study was designed to assess glucose metabolism in hepatocellular carcinoma (HCC) with PET and [18F]fluorodeoxyglucose (FDG) and to compare the results with the measured in vitro enzymatic activity of glucose metabolism and the histologic grading of HCC.
METHODS: Dynamic FDG-PET scans were obtained in 17 preoperative patients with HCC. From the serial tissue and arterial radioactivities obtained by dynamic PET, FDG kinetic rate constants (K1 to k4) were obtained. The standardized uptake value (SUV) was also determined from the images acquired 48 to 60 min after FDG administration. These PET results were compared with hexokinase and glucose-6-phosphatase (G6Pase) activities and histologic grading of HCC in surgically resected tumor materials. According to histologic grading, the tumors were divided into low-grade and high-grade HCCs.
RESULTS: The k3 and SUV of high-grade HCCs were significantly higher than those of low-grade HCCs (p < 0.005, each). In addition, high correlations were observed between the hexokinase activities and these two parameters (r = 0.715 0.768, respectively). In some HCCs, relatively high G6Pase activities and k4 values modified tumor FDG uptake.
CONCLUSION: FDG PET is a valuable method for assessing glucose metabolism and histologic grading of HCC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562048

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  84 in total

1.  Liver-specific contrast agent-enhanced magnetic resonance and ¹⁸F-fluorodeoxyglucose positron emission tomography findings of hepatocellular adenoma: report of a case.

Authors:  Tatsuaki Sumiyoshi; Michihisa Moriguchi; Hideyuki Kanemoto; Kouiku Asakura; Keiko Sasaki; Teiichi Sugiura; Takashi Mizuno; Katsuhiko Uesaka
Journal:  Surg Today       Date:  2011-12-10       Impact factor: 2.549

Review 2.  18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.

Authors:  B B Chin; R L Wahl
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

3.  The effect of fasting on PET Imaging of Hepatocellular Carcinoma.

Authors:  Nathan Tenley; David J Corn; Lewis Yuan; Zhenghong Lee
Journal:  J Cancer Ther       Date:  2013-04

4.  Update of PET and PET/CT for hepatobiliary and pancreatic malignancies.

Authors:  Dominique Delbeke; William H Martin
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

5.  Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake.

Authors:  V Arena; A Skanjeti; R Casoni; A Douroukas; E Pelosi
Journal:  Radiol Med       Date:  2008-07-10       Impact factor: 3.469

6.  Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients.

Authors:  Nobuyuki Hayakawa; Yuji Nakamoto; Koya Nakatani; Etsuro Hatano; Satoru Seo; Tatsuya Higashi; Tsuneo Saga; Shinji Uemoto; Kaori Togashi
Journal:  Int J Clin Oncol       Date:  2013-12-25       Impact factor: 3.402

7.  Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Authors:  Leo Rasche; Edgardo Angtuaco; James E McDonald; Amy Buros; Caleb Stein; Charlotte Pawlyn; Sharmilan Thanendrarajan; Carolina Schinke; Rohan Samant; Shmuel Yaccoby; Brian A Walker; Joshua Epstein; Maurizio Zangari; Frits van Rhee; Tobias Meissner; Hartmut Goldschmidt; Kari Hemminki; Richard Houlston; Bart Barlogie; Faith E Davies; Gareth J Morgan; Niels Weinhold
Journal:  Blood       Date:  2017-04-21       Impact factor: 22.113

8.  Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.

Authors:  M G Caprio; A Cangiano; M Imbriaco; F Soscia; G Di Martino; A Farina; G Avitabile; L Pace; P Forestieri; M Salvatore
Journal:  Radiol Med       Date:  2009-12-16       Impact factor: 3.469

9.  Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Authors:  Daiki Yamashige; Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Nozomu Muraishi; Akira Kajiwara; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2020-11-18       Impact factor: 2.935

10.  Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Authors:  Satoshi Takeuchi; Eric M Rohren; Reham Abdel-Wahab; Lianchun Xiao; Jeffrey S Morris; Homer A Macapinlac; Manal M Hassan; Ahmed O Kaseb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.